← Leaderboards
Lieping Chen
Mayo Clinic Coll Of Medicine, Rochester
$19,852,609
Attributed
$22,514,587
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,514,587 · 17
By mechanism
R01$15,357,587 · 7
P50$3,965,510 · 5
U19$1,341,374 · 2
T32$1,289,835 · 1
R21$286,000 · 1
P30$274,281 · 1
Top collaborators
- Mario Sznol6 shared
- Drew M. Pardoll5 shared
- Suzanne Louise Topalian5 shared
- Roy S Herbst4 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Larry R Pease$8,572,263
- Mehrdad Mazlumzadeh$695
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteImmunityBaseTumorImmuneMalignant NeoplasmsResponseTumor ImmunityNovel StrategiesClinical TrialsImmune ResponseMolecularImmunotherapyLigandsDesignCancer PatientMediatingPathway InteractionsCancer TherapyReceptorProgramsResistanceCellsMouse Model
Grant awards (91)
Project 1: Siglec15 as a new target for lung cancer immunotherapy$366,580
P50 · FY2024 · CA · contact PI
Project 1: Siglec15 as a new target for lung cancer immunotherapy$353,055
P50 · FY2022 · CA · contact PI
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)$306,652
T32 · FY2022 · CA
Project 1: Siglec15 as a new target for lung cancer immunotherapy$362,378
P50 · FY2021 · CA · contact PI
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)$308,653
T32 · FY2021 · CA
Cancer Immunology Research Program$58,257
P30 · FY2021 · CA · contact PI
Project 1: Siglec15 as a new target for lung cancer immunotherapy$381,856
P50 · FY2020 · CA · contact PI
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)$345,257
T32 · FY2020 · CA
Cancer Immunology Research Program$58,257
P30 · FY2020 · CA · contact PI
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)$329,273
T32 · FY2019 · CA
Immunotherapy of Advanced Non-small Cell Lung Cancer$280,764
P50 · FY2019 · CA · contact PI
Yale SPORE in Lung Cancer Career Development Program$125,258
P50 · FY2019 · CA · contact PI
Cancer Immunology Research Program$58,257
P30 · FY2019 · CA · contact PI
Cancer Immunology Research Program$11,904
P30 · FY2019 · CA · contact PI
Immunotherapy of Advanced Non-small Cell Lung Cancer$205,678
P50 · FY2018 · CA · contact PI
Cancer Immunology Research Program$58,257
P30 · FY2018 · CA · contact PI
Yale SPORE in Lung Cancer Career Development Program$50,265
P50 · FY2018 · CA · contact PI
Cancer Immunology Research Program$11,905
P30 · FY2018 · CA · contact PI
Cancer Immunology Research Program$11,904
P30 · FY2018 · CA · contact PI
Cancer Immunology Research Program$2,857
P30 · FY2018 · CA · contact PI
Cancer Immunology Research Program$2,683
P30 · FY2018 · CA · contact PI
Immunotherapy of Advanced Non-small Cell Lung Cancer$299,595
P50 · FY2017 · CA · contact PI
Yale SPORE in Lung Cancer Career Development Program$143,616
P50 · FY2017 · CA · contact PI
The PD-1/B7-H1 Pathway and Melanoma Immunity$108,120
P50 · FY2017 · CA · contact PI
Immunotherapy of Advanced Non-small Cell Lung Cancer$193,467
P50 · FY2016 · CA · contact PI
The PD-1/B7-H1 Pathway and Melanoma Immunity$155,783
P50 · FY2016 · CA · contact PI
Yale SPORE in Lung Cancer Career Development Program$47,249
P50 · FY2016 · CA · contact PI
Immunotherapy of Advanced Non-small Cell Lung Cancer$197,114
P50 · FY2015 · CA · contact PI
The PD-1/B7-H1 Pathway and Melanoma Immunity$157,440
P50 · FY2015 · CA · contact PI
Yale SPORE in Lung Cancer Career Development Program$48,196
P50 · FY2015 · CA · contact PI
B7-H1/PD-1 modulation in cancer therapy$443,937
R01 · FY2014 · CA
The PD-1/B7-H1 Pathway and Melanoma Immunity$154,864
P50 · FY2014 · CA · contact PI
B7-H1/PD-1 modulation in cancer therapy$437,199
R01 · FY2013 · CA
The PD-1/B7-H1 Pathway and Melanoma Immunity$169,207
P50 · FY2013 · CA · contact PI
B7-H1/PD-1 modulation in cancer therapy$471,842
R01 · FY2012 · CA
The PD-1/B7-H1 Pathway and Melanoma Immunity$165,025
P50 · FY2012 · CA · contact PI
B7-H1/PD-1 modulation in cancer therapy$479,334
R01 · FY2011 · CA
Memory T lymphocyte-mediated innate immunity$358,211
R01 · FY2011 · AI · contact PI
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE$355,772
R01 · FY2011 · CA · contact PI
B7-H1/PD-1 modulation in cancer therapy$510,450
R01 · FY2010 · CA
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE$363,450
R01 · FY2010 · CA · contact PI
Memory T lymphocyte-mediated innate immunity$358,370
R01 · FY2010 · AI · contact PI
Experimental Therapy of Cancer by Costimulated Immunity$325,256
R01 · FY2010 · CA · contact PI
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE$363,450
R01 · FY2009 · CA · contact PI
Memory T lymphocyte-mediated innate immunity$361,989
R01 · FY2009 · AI · contact PI
Experimental Therapy of Cancer by Costimulated Immunity$325,256
R01 · FY2009 · CA · contact PI
EVALUATE B7H1/H4 IN MOUSE MODELS AND IN HUMAN PRE-CLINICAL STUDIES$234,891
U19 · FY2009 · CA · contact PI
CORE--PROTEIN EXPRESSION$76,359
U19 · FY2009 · CA · contact PI
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE$363,450
R01 · FY2008 · CA · contact PI
Memory T lymphocyte-mediated innate immunity$361,989
R01 · FY2008 · AI · contact PI
Experimental Therapy of Cancer by Costimulated Immunity$325,256
R01 · FY2008 · CA · contact PI
CD137 Antibody for Cancer Therapy$317,808
R01 · FY2008 · CA · contact PI
EVALUATE B7H1/H4 IN MOUSE MODELS AND IN HUMAN PRE-CLINICAL STUDIES$234,896
U19 · FY2008 · CA · contact PI
CORE--PROTEIN EXPRESSION$76,931
U19 · FY2008 · CA · contact PI
Memory T lymphocyte-mediated innate immunity$369,000
R01 · FY2007 · AI · contact PI
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE$363,450
R01 · FY2007 · CA · contact PI
Experimental Therapy of Cancer by Costimulated Immunity$325,256
R01 · FY2007 · CA · contact PI
CD137 Antibody for Cancer Therapy$317,808
R01 · FY2007 · CA · contact PI
Therapeutic Manipulation of the B7-like Molecules$310,442
R01 · FY2007 · CA · contact PI
EVALUATE B7H1/H4 IN MOUSE MODELS AND IN HUMAN PRE-CLINICAL STUDIES$239,454
U19 · FY2007 · CA · contact PI
CORE--PROTEIN EXPRESSION$78,976
U19 · FY2007 · CA · contact PI
Immune regulation of the B7-H1 pathway$355,238
R01 · FY2006 · CA · contact PI
Experimental Therapy of Cancer by Costimulated Immunity$334,033
R01 · FY2006 · CA · contact PI
CD137 Antibody for Cancer Therapy$327,299
R01 · FY2006 · CA · contact PI
Therapeutic Manipulation of the B7-like Molecules$319,715
R01 · FY2006 · CA · contact PI
EVALUATE B7H1/H4 IN MOUSE MODELS AND IN HUMAN PRE-CLINICAL STUDIES$150,236
U19 · FY2006 · CA · contact PI
CORE--PROTEIN EXPRESSION$49,880
U19 · FY2006 · CA · contact PI
Immune regulation of the B7-H1 pathway$363,788
R01 · FY2005 · CA
CD137 Antibody for Cancer Therapy$335,175
R01 · FY2005 · CA
Therapeutic Manipulation of the B7-like Molecules$327,409
R01 · FY2005 · CA
EVALUATE B7H1/H4 IN MOUSE MODELS AND IN HUMAN PRE-CLINICAL STUDIES$149,814
U19 · FY2005 · CA
CORE--PROTEIN EXPRESSION$49,937
U19 · FY2005 · CA
Immune regulation of the B7-H1 pathway$363,788
R01 · FY2004 · CA
CD137 Antibody for Cancer Therapy$335,175
R01 · FY2004 · CA
EXPERIMENTAL THERAPY OF CANCER BY COSTIMULATED IMMUNITY$331,088
R01 · FY2004 · CA
CD137 Antibody for Cancer Therapy$302,375
R01 · FY2004 · CA
Therapeutic Manipulation of the B7-like Molecules$289,361
R01 · FY2004 · CA
EXPERIMENTAL THERAPY OF CANCER BY COSTIMULATED IMMUNITY$285,728
R01 · FY2004 · CA
Therapeutic Manipulation of the B7-like Molecules$116,085
R01 · FY2004 · CA
Immune regulation of the B7-H1 pathway$321,513
R01 · FY2003 · CA
Therapeutic Manipulation of the B7-like Molecules$289,361
R01 · FY2003 · CA
EXPERIMENTAL THERAPY OF CANCER BY COSTIMULATED IMMUNITY$285,728
R01 · FY2003 · CA
Novel strategies to prevent islet transplantation rejec*$143,000
R21 · FY2003 · AI
Immune regulation of the B7-H1 pathway$321,513
R01 · FY2002 · CA
EXPERIMENTAL THERAPY OF CANCER BY COSTIMULATED IMMUNITY$285,728
R01 · FY2002 · CA
4-1BB COSTIMULATORY RECEPTOR/LIGAND IN TUMOR IMMUNITY$234,093
R01 · FY2002 · CA
Novel strategies to prevent islet transplantation rejec*$143,000
R21 · FY2002 · AI
EXPERIMENTAL THERAPY OF CANCER BY COSTIMULATED IMMUNITY$285,728
R01 · FY2001 · CA
4-1BB COSTIMULATORY RECEPTOR/LIGAND IN TUMOR IMMUNITY$228,969
R01 · FY2001 · CA
EXPERIMENTAL THERAPY OF CANCER BY COSTIMULATED IMMUNITY$285,728
R01 · FY2000 · CA
4-1BB COSTIMULATORY RECEPTOR/LIGAND IN TUMOR IMMUNITY$223,994
R01 · FY2000 · CA